ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium

    Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis

    Tommy Gerschman1, Jordan Raugust2, Julia Brooks3, Nicole Johnson1, Nadia Luca4, Rebeka Stevenson1, Heinrike Schmeling5, Paivi Miettunen1 and Susanne Benseler4, 1Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 2Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, 3Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, 4Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 5University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada

    Background/Purpose:  Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
  • Abstract Number: 22 • 2017 Pediatric Rheumatology Symposium

    Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis

    Gabriela Guefen1, Kirsten Jenkins2, Lori Ponder2, Kelly A. Rouster-Stevens2,3, Patricia Vega-Fernandez2,3, Elaine S Ramsay2,3, Sheila Angeles-Han2,3 and Sampath Prahalad2,3,4, 1College of Arts and Sciences, Emory University, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Pediatrics, Emory University School of Medicine, Atlanta, GA, 4Human Genetics, Emory University School of Medicine, Atlanta, GA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Treatments include disease modifying anti-rheumatic drugs, commonly methotrexate (MTX), biologics including Etanercept…
  • Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium

    Clinical Features and Treatment Outcomes in Down’s Arthropathy

    Jordan T. Jones1 and Leena Danawala2, 1Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, 2University of Missouri-Kansas City School of Medicine, Kansas City, MO

    Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
  • Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium

    Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies

    Kelly Wise1, Dustin Lewis2, Bethanne Thomas2, Karla Jones3, Stephanie Lemle2, Darby MacDonald2, Fatima Barbar-Smiley2, Vidya Sivaraman2 and Cagri Yildirim-Toruner3, 1Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Rheumatology, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose:  Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes.  Biologics,…
  • Abstract Number: 52 • 2017 Pediatric Rheumatology Symposium

    How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study

    Daniel B. Horton1,2, Jomaira Salas3, Aleksandra Wec4, Timothy Beukelman5,6, Alexis Boneparth1, Ky Haverkamp7, Melanie Kohlheim8, Melissa Mannion5, Nandini Moorthy1, Sarah Ringold9 and Marsha Rosenthal2, 1Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 3Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, 4Rutgers, the State University of New Jersey, New Brunswick, NJ, 5Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Family Medicine, University of Washington School of Medicine, Seattle, WA, 8Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 9Seattle Children's Hospital, Seattle, WA

    Background/Purpose: Prior research has examined factors important to clinicians in deciding whether to withdraw therapy for inactive JIA, but little is known about the perspectives…
  • Abstract Number: 148 • 2017 Pediatric Rheumatology Symposium

    Oral Microbial Profile in Juvenile Idiopathic Arthritis

    Sriharsha Grevich1,2, Peggy Lee3, Jeffrey McLean3, Brian Leroux3, Sarah Ringold1,2, Kyle Hager4, Mitchell Brittnacher4, Hillary Hayden4, Samuel Miller4 and Anne Stevens1,2,5, 1University of Washington, Department of Pediatrics, Seattle, WA, 2Seattle Children's Hospital, Seattle, WA, 3University of Washington, School of Dentistry, Seattle, WA, 4University of Washington, Department of Microbiology, Seattle, WA, 5Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: Microbial communities in the mouth have been associated with the chronic inflammation of periodontitis and rheumatoid arthritis (RA), and there is higher prevalence of…
  • Abstract Number: 139 • 2017 Pediatric Rheumatology Symposium

    Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis

    Amita Aggarwal1 and Sushma Singh2, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose:  Enthesitis related arthritis (ERA) is the most common category of JIA in Asia. Identifying dysregulated microRNA may help in understanding the pathogenesis of ERA.…
  • Abstract Number: 13 • 2017 Pediatric Rheumatology Symposium

    Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis

    Angela Taneja1, Sampath Prahalad2, Aimee O. Hersh3, Lori Ponder4, Lai Hin Kimi Chan5, Kelly A. Rouster-Stevens6, Anne E Tebo7, Subramanian Kugathasan8 and John F. Bohnsack9, 1Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, 2Pediatrics, Emory Children's Center, Atlanta, GA, 3Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, 4Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, 5Pediatrics, Emory University School of Medicine, Atlanta, GA, 6Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, 7University of Utah, Salt Lake City, UT, 8Gastroenterology, Emory University School of Medicine, Atlanta, GA, 9Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT

      Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis of childhood. The prevalence of autoimmunity is higher in JIA cases and relatives.…
  • Abstract Number: 66 • 2017 Pediatric Rheumatology Symposium

    Feasibility Testing of An Internet-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

    Jennifer N. Stinson1, Mark Connelly2, Adam Huber3, Nadia Luca4, Lynn R. Spiegel5, Argerie Tsimicalis6, Stephanie Luca7, Naweed Tajuddin7, Roberta Berard8, Julie Barsalou9, Sarah Campillo10,11, Brian Feldman12, Shirley M.L. Tse13, Paul Dancey14, Ciarán M. Duffy15, Nicole Johnson16, Patrick McGrath3, Natalie J. Shiff17, Lori Tucker18 and J. Charles Victor19, 1Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, 2Children's Mercy Hospital, Kansas City, MO, 3IWK Health Centre, Halifax, NS, Canada, 4Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 5Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 6McGill University, Montreal, QC, Canada, 7The Hospital for Sick Children, Toronto, ON, Canada, 8Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, 9CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, 10Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, 11Montreal Children's Hospital, Montreal, QC, Canada, 12Department of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 13Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 14Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, 15Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 16Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 17University of Florida, Gainesville, FL, 18Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, 19University of Toronto, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic illness in childhood. The responsibility of JIA management during the younger years is shared among family…
  • Abstract Number: 15 • 2017 Pediatric Rheumatology Symposium

    An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial

    Jennifer N. Stinson1, Sarah Campillo2, Tania Cellucci3, Paul Dancey4, Ciarán M. Duffy5, Janet Ellsworth6, Brian Feldman7, Adam Huber8, Nicole Johnson9, Patrick McGrath8, Alan Rosenberg10, Natalie J. Shiff11, Lynn R. Spiegel12, Shirley M.L. Tse13, Lori Tucker14, J. Charles Victor15 and Stephanie Luca16, 1Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, 2Montreal Children's Hospital, Montreal, QC, Canada, 3Pediatrics/Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, 4Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, 5Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 6University of Alberta, Edmonton, AB, Canada, 7Department of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 8IWK Health Centre, Halifax, NS, Canada, 9Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 10Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 11University of Florida, Gainesville, FL, 12Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 13Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 14Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, 15University of Toronto, Toronto, ON, Canada, 16The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness associated with physical and emotional symptoms that can negatively impact health-related quality of life…
  • Abstract Number: 157 • 2017 Pediatric Rheumatology Symposium

    Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis

    Laura Ballenger1 and Kyla Driest2, 1Nationwide Children's Hospital, Columbus, OH, 2Rheumatology, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) and can be completely asymptomatic until vision loss develops. In order to…
  • Abstract Number: 40 • 2017 Pediatric Rheumatology Symposium

    Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit

    Nadia Luca1, Evelyn Rozenblyum2, April Elliott3, Lynn R. Spiegel4, Nicole Johnson5, Sara Ahola Kohut6, Yvonne Brandelli3, Carolyn Johns7, Stephanie Luca8, Dianne P. Mosher9, Gordon Soon10, Karine Toupin-April11, Gabriela Uifalusi3 and Jennifer N. Stinson12, 1Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 2Royal University Hospital, Saskatoon, SK, Canada, 3Alberta Children's Hospital, Calgary, AB, Canada, 4Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 5Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 6Hospital for Sick Children, Toronto, ON, Canada, 7Alberta Health Services, Calgary, AB, Canada, 8The Hospital for Sick Children, Toronto, ON, Canada, 9Med, University of Calgary, Calgary, AB, Canada, 10Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 11Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, 12Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: A seamless transition from pediatric to adult care is critical to ensure optimal health outcomes in adolescents and young adults with Juvenile Idiopathic Arthritis…
  • Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium

    Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study

    Sarah Ringold1, George A. Tomlinson2, Pamela F. Weiss3, Laura E. Schanberg4, Brian M. Feldman5, Mary Ellen Riordan6, Anne C. Dennos7, Vincent Del Gaizo8, Kate Murphy9, Yukiko Kimura6 and the CARRA Registry Investigators, 1Seattle Children's Hospital, Seattle, WA, 2Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 4Pediatrics, Duke Medical Center, Durham, NC, 5Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 6Hackensack University Medical Center, Hackensack, NJ, 7Duke Clinical Research Institute, Durham, NC, 8Parent Partner, Whitehouse Station, NJ, 9Patient Partner, San Francisco, CA

    Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
  • Abstract Number: 25 • 2017 Pediatric Rheumatology Symposium

    Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network

    Brandt Groh1, Ottar Kristinsson2, Lisabeth V. Scalzi3, C. April Bingham4, Ronald Laxer5, Cagri Yildirim-Toruner6, Esi Morgan7, Michelle Batthish8, Beth Gottlieb9, Julia G. Harris10, Murray Passo11, Michael Shishov12 and Sheetal S. Vora13, 1Pediatrics, Penn State Milton S. Hershey Medical Center, Hershey, PA, 2Pediatrics, Penn State Children's Hospital, Hershey, PA, 3Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, 4Penn State Health Children's Hospital, Hershey, PA, 5Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Rheumatology, Nationwide Children's Hospital, Columbus, OH, 7Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, 9Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 10Children's Mercy - Kansas City, Kansas City, MO, 11Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, 12Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, 13Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC

    Background/Purpose: Within the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), the Physician Global Assessment (PhGA) metric is a key determinant of Òclinically inactiveÓ juvenile…
  • Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium

    The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA

    Joost Swart1, Nico Wulffraat2, Sytze de Roock3 and Pieter van Dijkhuizen4, 1Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, 2Wilhelmina Children’s Hospital, Utrecht, Netherlands, 3Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology